BNB Plus Corp is a micro-cap company that has repositioned itself as a digital asset treasury company, with BNB — the native cryptocurrency of the Binance blockchain ecosystem — as its primary reserve asset. The company's core strategy is to accumulate BNB using capital raised through equity offerings, then generate yield by deploying BNB through staking, liquidity provision, and other DeFi mechanisms on the Binance ecosystem. BNB Plus outsources management of its BNB holdings to Cypress LLC under a fee arrangement; notably, both the Chairman and Chief Investment Officer are affiliates of Cypress. As of mid-December 2025, the company held approximately 18,830 BNB acquired at an average cost of roughly $895 per token. BNB Plus also operates LineaRx, a subsidiary that develops and sells cell-free, enzymatic platforms for manufacturing synthetic DNA and RNA used as inputs in mRNA therapeutics, gene therapies, and in vitro diagnostics. LineaRx's core products — LineaDNA, LineaRNAP, and LineaIVT — are sold directly to biopharma developers, CDMOs, and researchers. The company argues its cell-free approach offers faster turnaround and a simpler manufacturing workflow versus traditional plasmid-based DNA production. LineaRx remains pre-profitability and management has stated a goal of licensing or selling the business outright. BNB Plus was formerly known as Applied DNA Sciences and underwent multiple restructurings in 2025, reducing headcount by roughly 72% and exiting its DNA tagging and clinical lab businesses in the process.